

Further Studies on Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as Potent and Selective Human A₁ Adenosine Receptor Antagonists

Maria Paola Giovannoni^{a*}, Giovanna Ciciani^a, Agostino Cilibrizzi^b, Letizia Crocetti^a, Simona Daniele^c, Lorenzo Di Cesare Mannelli^d, Carla Ghelardini^d, Chiara Giacomelli^c, Gabriella Guerrini^a, Claudia Martini^c, Maria Letizia Trincavelli^c, Claudia Vergelli^a

^aNEUROFARBA, Sezione Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.

^bDepartment of Chemistry, Imperial College London, South Kensington, London SW7 2AZ, UK.

^cDipartimento di Farmacia, Università degli Studi di Pisa, Via Bonanno 6, 56126 Pisa, Italy

^dNEUROFARBA, Sezione Farmacologia e Tossicologia, Università degli Studi di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy.

* To whom correspondence should be addressed

Maria Paola Giovannoni

Dipartimento NEUROFARBA, Sezione Farmaceutica e Nutraceutica

Via Ugo Schiff 6

Sesto Fiorentino 50019 Firenze

Tel +39-055-4573682

Fax +39-055-4573780

E-mail mariapaola.giovannoni@unifi.it

DOI: 10.1016/j.ejmech.2014.10.020

Abstract

A new series of pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones was synthesized and tested in radioligand binding assays on human A₁, A_{2A} and A₃ adenosine receptors. Most of the compounds showed high selectivity of action towards A₁ receptor and high affinity with K_i values in the low nanomolar range. The pharmacological profile of the most active molecules towards A₁ adenosine receptors was evaluated in cAMP functional assay. Compounds demonstrated their ability to completely counteract the effect of the agonist NECA, thus demonstrating their antagonist profile. Moreover, the most interesting compound, tested in the mouse passive avoidance, exhibited an anti-amnesic effect at the doses of 10 and 30 mg/kg.

Keywords:

Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones; human adenosine receptor; A₁ subtype; selectivity.

1. Introduction

Adenosine is an endogenous modulator that operates a wide variety of physiological functions in the nervous, cardiovascular, renal and immune systems, through the interaction with four different adenosine receptors (ARs) classified as A₁, A_{2A}, A_{2B} and A₃ [1-3]. All four ARs have been cloned from different species (including humans) and pharmacologically characterized [2,4].

ARs belong to G protein-coupled receptor (GPCRs) family and consist of a single polypeptide chain that passes through the membrane to form seven transmembrane helices. A₁ and A₃ receptors inhibit adenylate cyclase *via* Gi protein thus reducing the production of cyclic AMP (cAMP). Conversely the A_{2A} and A_{2B} subtypes stimulate the production of cAMP by coupling to Gs or Golf [5] protein. Nevertheless, ARs interact with other second messengers systems, such as phospholipase C (PLC) [6] (A₁, A_{2B} and A₃ subtype), phospholipase D (PLD) [7] (A₃ subtypes) and potassium and calcium channels [2,8] (A₁ subtype).

The potential therapeutic applications of selective ligands of ARs have been investigated in recent years for the treatment of several pathologies such as cardiovascular and renal diseases, CNS disorders, inflammatory and allergic disorders and cancer [9-11]. The A₁ARs are expressed at high levels in brain, cortex, cerebellum and hippocampus. Thus, the use of selective A₁ antagonists has emerged as potential target for the treatment of cognitive deficit, and for CNS disorders as Alzheimer's and Parkinson's diseases [12,13] as well as CNS-stimulatory drugs. In fact it is known that anti-amnesic activities is exhibited by adenosine A₁ antagonists [14] such as DPCPX which is effective in altering memory, promoting a facilitation [15,16] and in preventing methylphenidate-triggered recognition memory impairment in adult mice [17] and 8-cyclopentyl-1,3-dimethylxanthine which exerts a positive impact on hippocampus-dependent spatial object recognition memory [18].

By contrast, the selective activation of A₁ ARs significantly impaired retention performance as demonstrated by the treatment with N⁶-cyclopentyladenosine (CPA) that is also able to impair memory retrieval for inhibitory avoidance task into posterior cingulate cortex [19]. Furthermore, the CPA derivative 2-Chloro-N⁶-cyclopentyladenosine disrupted the juvenile recognition ability of adult rats [20].

With regards to possible application of A₁AR antagonists in cardiovascular system, kidney and respiratory pathologies, different drugs are under development for the treatment of asthma [21], cardiac arrhythmia, heart failure, renal failure and hypertension [22].

Currently, the potent and selective A₁R antagonists **BG9928** (Tonapofylline) [23], **SLV320** [24] and **KW-3902** (Rolofylline) [25,26] are in clinical trials (phase II/phase III) for the treatment of congestive heart failure and renal insufficiency (Figure 1).

Our research in this field was first performed by synthesizing compounds that respected the classical structural requirements proposed by Jacobson et al. [27] for adenosine receptor antagonists. The pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones nucleus of our compounds proved to be an appropriate scaffold for adenosine receptor subtype hA₁ as demonstrated by the high activity and selectivity of the most interesting terms [28,29]. The various positions of the tricyclic scaffold have been investigated and results available so far showed that the optimal substituents are a pyridyl ring at position 1, benzyl at N-3, hydrogen or methyl at position 6 and a phenyl at position 9 (compounds **A** [28] is reported as example in Figure 1).

In the present work we further investigated position 1 (in which we previously inserted phenyl, 3- and 4-F-phenyl, 3- and 4-pyridyl, chlorine and methyl) [28,29] including (hetero)aryl and (cyclo)alkyl groups and maintaining at the other positions the substituents which award the

maximum activity. For some active compounds, the corresponding 4-thione derivatives were synthesized in order to better understand the importance of the amide carbonyl group.

2. Chemistry

The synthetic procedure previously described³⁰⁻³² affording the final pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones **5a-i**, **16a-i** (**16e**³²) and **17a-i** is depicted in Scheme 1 and Scheme 2.

In Scheme 1 isoxazolo[3,4-d]pyridazinones **1a** [33], **1b** and **1c** [34] were treated with benzyl chloride in anhydrous DMF and K₂CO₃ to give the corresponding N-benzyl derivatives **2a**, **2b** [35] and **2c**. On the bicyclic system a condensation with benzaldehyde in MeONa was performed to give rise the styryl derivatives **3a-c**, which, in turn, were treated with hydrazine hydrate in EtOH to afford the pyrazolo intermediates **4a-c** through reductive isoxazole ring opening and closure to pyrazole at position 5 of the pyridazinone system. To obtain the final tricyclic compounds **5a-i**, the intermediated **4a-c** were then treated with the appropriate anhydride (for 6-methyl and 6-ethyl derivatives **5b,c**, **5e,f**, **5h,i**) or with triethylorthoformate, catalytic amount of concentrated sulphuric acid in anhydrous DMF (for 6-unsubstituted **5a**, **5d**, **5g**).

Scheme 2 depicts the synthetic route to introduce different substituents at position 1 of the tricyclic system such as cC₆H₁₁, cC₅H₉ and nC₄H₉. The synthesis of isoxazoles **8a-c** (**8a** [36] and **8b** [33]) and **9a-c** starting from appropriate diketones **6a-c** [37-39] and commercially available chloro(hydroximino)acetate **7** doesn't occur through a regioselective 1,3-dipolar cycloaddition, but led to a mixture of the two isomers **8** and **9**, 4-COCH₃ and 4-COR derivatives respectively, which were separated by column chromatography. Each isomer was transformed into the corresponding isoxazolepyridazinone of type **10** or **11** with hydrazine in EtOH and then in the N-

benzyl derivative **12** or **13**. All compounds of type **8-13** were purified and completely characterized. However, the separation of the two isomers **8** and **9** is very difficult and the yields are so low that limit all the synthetic route. Rather than on the pure isomer, we therefore considered it more convenient to work on the mixture of isomers **8** and **9**, to perform the closure to isoxazolepyridazinones (mixture of **10** and **11**) and to alkylate with benzyl chloride (mixture of **12** and **13**). Between these last isomers, only compounds of type **12** react with benzaldehyde because of the activated methyl group at position 3 [40], affording the styryl derivatives **14** which are insoluble in the reaction medium and are recovered by suction. Compounds of type **14** then undergo the same sequence of reaction previously described in Scheme 1 to furnish the tricyclic compounds **16 a-i** (**16e** [32]) which were further treated with Lawesson's reagent in toluene to afford the final thioderivatives **17a-i**.

3. Pharmacology

The biological activity of compounds **5**, **16** and **17** towards adenosine receptors was evaluated by radioligand binding assays and functional experiments. Compound affinity towards human A₁, A_{2A} and A₃ adenosine receptors were reported in Tables 1 and 2. The results were obtained by competition binding experiments and expressed as K_i (nM) or inhibition percentage at 10 μM.

In addition, the selectivity towards the A_{2B} subtype of some of compounds active on A₁ was assessed with functional experiments (Table 3). All the tested compounds presented no significant activity as agonist and antagonist on A_{2B} receptor. Then, the pharmacological profile of the two promising compounds, showing high affinity and selectivity for A₁ adenosine receptors (**16e** and **16i**), together with two inactive compounds (**5c** and **5f**), was evaluated by functional cAMP assay, as reported in Figure 2.

Finally, the most potent and selective compounds (**16i**) was tested to investigate its potential anti-amnesic profile in the presence of amnesia induced by A₁ selective agonist (Table 4).

4. Results and discussion

SAR analyses were performed by considering two groups of compounds which at position 1 present an aromatic substituent (**5a-i**) or a (cyclo)alkyl group (**16a-i** and **17a-i**).

Starting from the 1-(hetero)aryl derivatives **5a-i** (Table 1) we can observe that the substitution in the lead compound **A** of the pyridine with 4-chlorophenyl or thiophene (2 or 3-thienyl) led to inactive products with a very low inhibition (I% = 8-65 at 10 μM) on all three ARs. The only exception is represented by three compounds belonging to the 1-thienyl series (**5d**, **5g** and **5e**) for which an unexpected and not yet explained activity and selectivity appears toward hA_{2A} subtype. In fact, compounds **5d** and **5g** showed a K_i values of 51.0 ± 3.1 and 69.2 ± 4.4 nM respectively for hA_{2A} adenosine receptor and low affinity for hA₁ and hA₃; while compound **5e** showed an affinity towards the hA_{2A} subtype only in the micromolar range.

On the other hand, the replacement of the aromatic at position 1 with a (cyclo)alkyl group (compounds **16a-i**, Table 2) was associated with a remarkable improvement of activity and/or selectivity. The introduction of a cyclohexyl (**16a-c**) furnished hA₁ selective ligands depending on the substituent at position 6. In fact compounds bearing a methyl or an ethyl group (**16b** and **16c**) showed a very good affinity for hA₁ subtype (K_i = 9.5±0.7 and 15.2 ±1.1 nM respectively) together with an excellent selectivity toward hA_{2A}, hA_{2B} and hA₃. Elimination of the substituent (**16a**) led to a hA₁/hA₃ mixed ligand with micromolar affinity. 1-Cyclopentyl derivatives **16d-f** showed a similar trend, being the unsubstituted term **16d** the less active and no selective (it binds

all three subtype receptors with the same affinity), whereas **16e** and **16f** are more potent and selective ($K_i = 6.2 \pm 0.2$ and 3.5 ± 0.4 nM for hA₁ respectively). The introduction at R1 of the linear chain n-butyl afforded the best results since compounds **16g-i** displayed high potency on hA₁ with K_i in the low nanomolar range ($K_i = 1.9 \pm 0.2$, 3.4 ± 0.3 and 1.4 ± 0.1 nM, respectively) and a good selectivity versus the other subtypes. The ethyl derivative **16i** is endowed with the best affinity ($K_i = 1.4 \pm 0.1$ nM) and selectivity (7% and 20% of inhibition at 10 μ M for hA_{2A} and hA₃ respectively).

These data suggest that lipophilicity and a suitable steric hindrance of the groups linked at position 1 are very important requirements for the binding at hA₁ subtype receptor and the n-butyl seems the best among the substituents till now inserted. The appearance of a mild affinity in the 6-unsubstituted derivatives **16a**, **16d** and **16g** toward other subtypes receptor, in particular hA₃, could be the consequence of the lack of interaction of the alkyl group at position 6 at the binding site and a subsequent rearrangement of the molecule at the binding site (data not shown). With the aim to better define the importance of the carbonyl at position 4, whose role has been previously investigated only in part [28], and taking into account the favorable substitutions of C=O with C=S reported in the literature [41] we synthesized the corresponding 4-thio derivatives of the active **16a-i**. The biological results of the new compounds **17a-i** have provided information not easy to interpret, as reported in Table 2. In fact, in most cases, the transformation in 4-C=S derivatives led to the loss of affinity for hA₁ subtype and only the 6-unsubstituted **17a**, **17d** and **17g**, regardless of the nature of the 1-substituent, retain the activity. The exception to this trend is represented by the 6-ethyl derivative **17f** which maintained affinity for hA₁ ($K_i = 4.7 \pm 0.5$ nM). All the active molecules of type **17** showed very good hA₁ selectivity and similarly to the series of 4-C=O, the most potent compound belongs to the 1-butyl derivatives (compound **17g**, $K_i = 2.4 \pm 0.2$ nM). To explain the different trend of activity of the 4-C=O and 4-S=O

series, it could be invoked the different steric hindrance of the sulfur-containing molecular part which could adopt different conformations with respect to the oxygen-containing derivatives, such that only the 6-unsubstituted pyrazolopyrimidopyridazin-4(3H)-ones can keep hA₁ affinity (data not shown).

The pharmacological profile of compounds **16e** and **16i**, that showed high A₁ AR affinity and selectivity, in parallel with the inactive compounds **5c** and **5f**, was further investigated by cAMP functional assay (Figure 2). The assay was performed evaluating the effect of the above products on NECA-mediated cAMP inhibition in CHO cells expressing the hA₁ receptor. The results showed that **16e** and **16i** were able to counteract the inhibitory effect of the A₁ adenosine receptor agonist NECA on cAMP production with an IC₅₀ value of 5.1 ± 0.2 and 2.9 ± 0.1 nM, respectively, thus demonstrating their antagonist profile. These values are completely in accordance with hA₁ binding affinity values ($K_i = 6.2 \pm 0.2$ and 1.4 ± 0.1 nM respectively) obtained in radioligand binding studies. Viceversa, compounds **5c** and **5f**, were completely inactive in the functional, as well as in the binding assay confirming they were not able to bind human A₁ AR subtypes.

Finally, according with the anti-amnesic activity showed by adenosine A₁ antagonist [14], compound **16i** was investigated in the mouse passive avoidance test to evaluate its anti-amnesic profile and the results are showed in Table 4.

The amnesia induced by CPA (1,6 mg/kg i.p.) was prevented, by pretreatment with the A₁ selective antagonist DPCPX (3 mg/kg i.p.) and with **16i** at the dose of 10 and 30 mg/kg p.o. whereas the dose of **16i** of 3 mg/kg p.o. was devoid of anti-amnesic effect.

The efficacy showed by **16i** is comparable with that exhibited by DPCPX but its potency is about a third lower. Finally, the examined compounds reach its maximal anti-amnesic effect at the dose of 10 mg/kg p.o. since the dose three times higher is equally active.

It should be noted that all drugs under investigation elicited their modulatory effect on cognitive processes without changing either gross behavior or motor coordination, as revealed by the rota-rod test in which the number of falls in the rota-rod test progressively decreased, since mice learned how to balance on the rotating rod (data not shown). None of the drugs at the employed doses increased the number of falls from the rotating rod in comparison with saline and CMC-treated mice (data not shown).

5. Conclusions

In conclusion, the present study provided new potent and selective hA₁ adenosine receptor antagonists belonging to the class of pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones. The presence of a cyclo/alkyl group at position 1 led to a series of compounds with a remarkable improvement of hA₁ AR affinity and selectivity. Compound **16i** reveals the most interesting of the series for its affinity (hA₁ K_i = 1.4±0.1 nM) and selectivity (7% and 20% of inhibition at 10 μM for hA_{2A} and hA₃ respectively). Thus, the pharmacological profile of this compound as A₁ antagonist was demonstrated by functional assay. Furthermore, the anti-amnesic effect of **16i** was evaluated in the mouse passive avoidance test. The administration of acute doses of **16i** exert a pro-cognitive effect by reverting the amnesia induced by the stimulation of A₁ adenosine receptor, in accordance with its A₁ antagonism.

6. Experimental section

6.1. Chemistry

Reagents and starting materials were obtained from commercial sources. Extracts were dried over Na₂SO₄, and the solvents were removed under reduced pressure. All reactions were monitored by thin layer chromatography (TLC) using commercial plates precoated with Merck

silica gel 60 F-254. Visualization was performed by UV fluorescence ($\lambda_{\text{max}} = 254 \text{ nm}$) or by staining with iodine or potassium permanganate. Chromatographic separations were performed on a silica gel column by gravity chromatography (Kieselgel 40, 0.063-0.200 mm; Merck), flash chromatography (Kieselgel 40, 0.040-0.063 mm; Merck), silica gel preparative TLC (Kieselgel 60 F₂₅₄, 20 x 20 cm, 2 mm), or a CombiFlash[®] Rf System (using RediSep[®] Rf Silica Columns, Teledyne Isco, Lincoln, Nebraska, USA). Yields refer to chromatographically and spectroscopically pure compounds, unless otherwise stated. Compounds were named following IUPAC rules, as applied by Beilstein-Institut AutoNom 2000 (4.01.305) or CA Index Name. All melting points were determined on a microscope hot stage Büchi apparatus and are uncorrected. The identity and purity of intermediates and final compounds was ascertained through ¹H NMR and TLC chromatography. ¹H NMR and ¹³C NMR spectra were recorded with Avance 400 instruments (Bruker Biospin Version 002 with SGU). Chemical shifts (δ) are reported in ppm to the nearest 0.01 ppm using solvent as the internal standard. Coupling constants (J values) are given in Hz and were calculated using 'TopSpin 1.3' software rounded to the nearest 0.1 Hz. Mass spectra (m/z) were recorded on an ESI-TOF mass spectrometer (Bruker Micro TOF), and reported mass values are within the error limits of ± 5 ppm mass units. Microanalyses indicated by the symbols of the elements or functions were performed with a Perkin-Elmer 260 elemental analyzer for C, H, and N, and they were within $\pm 0.4 \%$ of the theoretical values.

6.1.1. General procedure for 2a and 2c. A suspension of isoxazolopyridazinone **1a**²⁶ or **1c**²⁷ (1.3 mmol), K₂CO₃ (2.6 mmol) and 1.3-1.7 mmol of benzyl chloride in anhydrous DMF (2.5 mL) was stirred at 80 °C for 2-3 h. After cooling, cold water was added and the precipitate was recovered by suction.

6.1.1.1. 6-Benzyl-4-(4-chlorophenyl)-3-methyl-6H-isoxazolo[3,4-d]pyridazin-7-one [2a].

Yield = 83%; mp = 143-145 °C (EtOH); ¹H-NMR (CDCl₃) δ 2.55 (s, 3H, CH₃), 5.40 (s, 2H, CH₂Ph), 7.30-7.55 (m, 9H, Ar). ESI-MS calcd. for C₁₉H₁₄ClN₃O₂, 351.79; found: *m/z* 352.49 [M+H]⁺. Anal. C₁₉H₁₄ClN₃O₂ (C, H, N).

6.1.2. General procedure for 3a-c. To a suspension of 1 mmol of **2a-c** (**2b**²⁸) and 2.3-2.5 mmol of benzaldehyde in anhydrous MeOH (2-3 mL), MeONa (1-1.5 mmol) was added. The mixture was stirred at 60 °C for 1-30 min. After cooling, the precipitate was recovered by suction.

6.1.2.1. 6-Benzyl-4-(4-chlorophenyl)-3-styryl-6H-isoxazolo[3,4-d]pyridazin-7-one [3a].

Yield = 72%; mp = 177-179 °C (EtOH); ¹H-NMR (CDCl₃) δ 5.40 (s, 2H, CH₂Ph), 6.80 (d, 1H, CH=CH-Ph, J = 16.4 Hz), 7.35-7.60 (m, 14H, Ar), 7.65 (d, 1H, CH=CH-Ph, J = 16.2 Hz). ESI-MS calcd. for C₂₆H₁₈ClN₃O₂, 439.89; found: *m/z* 440.67 [M+H]⁺. Anal. C₂₆H₁₈ClN₃O₂ (C, H, N).

6.1.3. General procedure for 4a-c. To a suspension of compounds **3a-c** (0.45 mmol) in EtOH (3-4 mL), 5-10 mmol of hydrazine hydrate were added and the mixture was stirred at room temperature for 2-4 h. After concentration under vacuum and addition of cold water (10-15 mL), the final products precipitate and were filtered off by suction.

6.1.3.1. 4-Amino-2-benzyl-6-(4-chlorophenyl)-5-(5-phenyl-2H-pyrazol-3-yl)-2H-

pyridazin-3-one [4a]. Yield = 68%; mp = 234-235 °C (EtOH); ¹H-NMR (CDCl₃) δ 5.40 (s, 2H, CH₂Ph), 5.70 (s, 1H, Ar), 6.30 (exch br s, 2H, NH₂), 7.35-7.55 (m, 14H, Ar), 8.60 (exch

br s, 1H, NH). ESI-MS calcd. for C₂₆H₂₀ClN₅O, 453.92; found: *m/z* 454.68 [M+H]⁺. Anal.

C₂₆H₂₀ClN₅O (C, H, N).

6.1.4. General procedure for 5a, 5d and 5g. A mixture of **4a-c** (0.22 mmol), triethylorthoformate (15 mmol), anhydrous DMF (0.5-1 mL) and a catalytic amount of concentrated sulfuric acid was stirred at room temperature for 1-2 h. After cooling the precipitate was recovered by suction and purified by crystallization with ethanol.

6.1.4.1. 3-Benzyl-1-(4-chlorophenyl)-9-phenylpyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-one [5a]. Yield = 78%; mp = 219-220 °C (EtOH); ¹H-NMR (CDCl₃) δ 5.60 (s, 2H, CH₂Ph), 6.20 (s, 1H, Ar), 7.30-7.80 (m, 14H, Ar), 9.45 (s, 1H, Ar). ¹³C-NMR (CDCl₃) δ 158.81, 156.84, 147.81, 145.21, 143.12, 137.58, 136.01, 135.80, 131.87, 130.85, 129.18, 129.01, 128.74, 128.31, 128.01, 127.83, 125.62, 114.81, 103.81, 56.42. ESI-MS calcd. for C₂₇H₁₈ClN₅O, 463.92; found: *m/z* 464.73 [M+H]⁺. Anal. C₂₇H₁₈ClN₅O (C, H, N).

6.1.5. General procedure for 5b,c, 5e,f and 5h,i. A mixture of 4-amino-pyrazolyl derivatives **4a-c** (0.23 mmol) and the appropriate anhydride (11-15 mmol) was refluxed under stirring for 30 min-2 h. After cooling, the precipitate was recovered by suction. For compound **5b**, cold water was added and the mixture extracted with CH₂Cl₂ (3 x 15 mL). Removal of the solvent afforded compound **5b** which was crystallized from ethanol.

6.1.5.1. 3-Benzyl-1-(4-chlorophenyl)-6-methyl-9-phenylpyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-one [5b]. Yield = 82%; mp = 235-236 °C (EtOH); ¹H-NMR (CDCl₃) δ 3.20 (s, 3H, CH₃), 5.55 (s, 2H, CH₂Ph), 6.20 (s, 1H, Ar), 7.30-7.85 (m, 14H, Ar). ¹³C-NMR

(CDCl₃) δ 157.21, 154.83, 150.18, 148.21, 144.78, 142.01, 137.33, 136.21, 135.98, 132.01, 131.01, 130.81, 129.10, 128.81, 128.10, 127.81, 127.10, 126.02, 113.98, 102.11, 57.21, 20.98. ESI-MS calcd. for C₂₈H₂₀ClN₅O, 477.94; found: m/z 478.73 [M+H]⁺. Anal. C₂₈H₂₀ClN₅O (C, H, N).

6.1.6. General procedure for 8c and 9a-c. To a cooled (0 °C) and stirred solution of EtONa, obtained from Na^o (27 mmol) and anhydrous EtOH (80 mL), a solution of appropriate diketone **6a-c**³⁰⁻³² (27 mmol) in the same solvent (10-15 mL) was slowly added. Then the suspension was further cooled to -5 °C and a solution of ethyl chloro(hydroximino)acetate **7** (18 mmol) in anhydrous EtOH (20-25 mL) was added dropwise. Then the mixture was neutralized with 6N HCl, and the solvent was evaporated *in vacuo*. The residue oil was washed first with cold 0.5 N NaOH and then with cold water, and finally it was extracted with CH₂Cl₂ (3 x 20 mL). Evaporation of the solvent afforded a mixture of isomers **8** and **9** which were purified by column chromatography, using cyclohexane/ethyl acetate 4:1 as eluent, for compound **8c** and **9c** and cyclohexane/ethyl acetate 9:1 for compound **9a** and **9b**.

6.1.6.1. 5-Methyl-4-pentanoylisoxazole-3-carboxylic acid ethyl ester [8c]. Yield = 30%; oil; ¹H-NMR (CDCl₃) δ 0.90 (t, 3H, (CH₂)₃CH₃, J = 7.2 Hz), 1.35 (m, 2H, (CH₂)₂CH₂CH₃), 1.40 (t, 3H, COOCH₂CH₃, J = 7.2 Hz), 1.65 (m, 2H, CH₂CH₂CH₂CH₃), 2.65 (s, 3H, CH₃), 2.80 (t, 2H, CH₂CH₂CH₂CH₃, J = 7.2 Hz), 4.45 (q, 2H, COOCH₂CH₃, J = 7.2 Hz). ESI-MS calcd. for C₁₂H₁₇NO₄, 239.27; found: m/z 240.08 [M+H]⁺. Anal. C₁₂H₁₇NO₄ (C, H, N).

6.1.7. General procedure for 10a,c and 11a-c. To a solution of the pure isoxazole **8** or **9** (**8a,b**^{29,25} si lascia o si toglie avendo levato 8a-c) (2 mmol) in EtOH (2-4 mL), hydrazine hydrate

(3-4 mmol) was added. The mixture was stirred at room temperature for 1-2 h, concentrated under vacuum and added of 10-15 mL of cold water to afford the solid final compounds **10a,c** and **11a-c** which were filtered off by suction.

6.1.7.1. 4-Cyclohexyl-3-methyl-6H-isoxazolo[3,4-d]pyridazin-7-one [10a]. Yield = 73%; mp = 168-171 °C (EtOH); ¹H-NMR (CDCl₃) δ 1.35-1.50 (m, 3H, cC₆H₁₁), 1.60 (m, 3H, cC₆H₁₁), 1.80 (m, 1H, cC₆H₁₁), 1.90-2.00 (m, 3H, cC₆H₁₁), 2.80 (m, 1H, cC₆H₁₁), 2.90 (s, 3H, 3-CH₃), 9.40 (exch br s, 1H, NH). ESI-MS calcd. for C₁₂H₁₅N₃O₂, 233.27; found: *m/z* 234.12 [M+H]⁺. Anal. C₁₂H₁₅N₃O₂ (C, H, N).

6.1.8. General procedure for 12a-c and 13a-c. Compounds **12a-c** and **13a-c** were obtained following the procedure reported for compounds **2a** and **2c** starting from isoxazolopyridazinones **10a-c** (**10b**²⁸) and **11a-c**. After cooling, cold water was added and the suspension was extracted with CH₂Cl₂ (3 x 15 mL). Removal of the solvent *in vacuo*, gave rise the final solid compounds.

6.1.8.1. 6-Benzyl-4-cyclohexyl-3-methyl-6H-isoxazolo[3,4-d]pyridazin-7-one [12a]. Yield = 83%; mp = 140-143 °C (EtOH); ¹H-NMR (CDCl₃) δ 1.25-1.45 (m, 4H, cC₆H₁₁), 1.55-1.65 (m, 1H, cC₆H₁₁), 1.75-1.85 (m, 1H, cC₆H₁₁), 1.90-2.00 (m, 4H, cC₆H₁₁), 2.70-2.80 (m, 1H, cC₆H₁₁), 2.85 (s, 3H, 3-CH₃), 5.30 (s, 2H, CH₂Ph), 7.25-7.35 (m, 3H, Ar), 7.50 (d, 2H, Ar). ESI-MS calcd. for C₁₉H₂₁N₃O₂, 323.39; found: *m/z* 324.18 [M+H]⁺. Anal. C₁₉H₂₁N₃O₂ (C, H, N).

6.1.9. General procedure for 14a-c. Compounds **14a-c** were obtained following the same general procedure described for **3a-c**, starting from isoxazolopyridazinones **12a-c**.

6.1.9.1. 6-Benzyl-4-cyclohexyl-3-styryl-6H-isoxazolo[3,4-d]pyridazin-7-one [14a]. Yield = 72%; mp = 156-157 °C (MeOH); ¹H-NMR (CDCl₃) δ 1.30-1.70 (m, 5H, cC₆H₁₁), 1.80-1.90 (m, 1H, cC₆H₁₁), 1.95-2.10 (m, 4H, cC₆H₁₁), 2.80-2.90 (m, 1H, cC₆H₁₁), 5.30 (s, 2H, CH₂Ph), 7.15 (d, 1H, CH=CH-Ph, J = 16.2 Hz), 7.25-7.60 (m, 10H, Ar), 7.80 (d, 1H, CH=CH-Ph, J = 16.4 Hz). ESI-MS calcd. for C₂₆H₂₅N₃O₂, 411.50; found: *m/z* 412.28 [M+H]⁺. Anal. C₂₆H₂₅N₃O₂ (C, H, N).

6.1.10. Alternative and more convenient synthesis of 14a-c. To a cooled (0 °C) and stirred solution of sodium ethoxide, obtained from sodium (54 mmol) and anhydrous EtOH (150 mL), a solution of the appropriate diketone **6a-c**³⁰⁻³² (54 mmol) in the same solvent (25 mL) was slowly added. Then the suspension was further cooled to -5 °C and a solution of ethyl chloro(hydroximino)acetate **7** (36 mmol) in anhydrous EtOH (40 mL) was added dropwise. Then the mixture was neutralized with 6N HCl, and the solvent was evaporated *in vacuo*. The residue oil was washed with cold 0.5 N NaOH and with cold water, and finally extracted with CH₂Cl₂ (3 x 40 mL). The solvent was evaporated, the crude oil (mixture of the isomers **8** and **9**) dissolved in 40 mL of EtOH, hydrazine hydrate (100 mmol) was added and the mixture stirred at room temperature for 1-2 h. EtOH was eliminated *in vacuo* and the addition of 180 mL of cold water afforded a suspension (a mixture of the isomers **10** and **11**) which was extracted with CH₂Cl₂ (3 x 30 mL). The organic layer was then evaporated and to the residue oil dissolved in anhydrous DMF (50 mL), was added with K₂CO₃ (100 mmol) and benzyl chloride (60 mmol) and the mixture was reacted for 2-3 h at 80°C. After cooling, cold water was added, the suspension was extracted with CH₂Cl₂ (3 x 30 mL) and after removal of the solvent a crude solid was recovered. In the same flask containing the solid, which is the mixture of the isomers **12** and **13**, benzaldehyde (100 mmol), MeONa (60 mmol) and anhydrous MeOH (30 mL) were added and

the mixture was heated at 60°C under stirring for 1-30 min. After cooling, the precipitate (compounds of type **14**) was recovered by suction.

6.1.11. General procedure for 15a-c. Compounds **15a-c** were obtained, starting from **14a-c**, following the general procedure described for compounds **4a-c**. For compound **15b**, after addition of cold water the mixture was extracted with ethyl acetate (3 x 15 mL) and the solvent was evaporated under vacuum to afford the final compound.

6.1.11.1. 4-Amino-2-benzyl-6-cyclohexyl-5-(5-phenyl-2H-pyrazol-3-yl)-2H-pyridazin-3-one [15a]. Yield = 96%; mp = 235-238 °C dec. (Cyclohexane); ¹H-NMR (DMSO-d₆) δ 0.90-1.90 (m, 10H, cC₆H₁₁), 2.90-3.00 (m, 1H, cC₆H₁₁), 5.25 (s, 2H, CH₂Ph), 6.15 (s, 1H, Ar), 6.80 (m, 2H, Ar), 7.20-7.55 (m, 6H, Ar), 7.80-7.90 (m, 2H, Ar), 12.90 (exch br s, 1H, NH), 13.60 (exch br s, 2H, NH₂). ESI-MS calcd. for C₂₆H₂₇N₅O, 425.53; found: *m/z* 426.29 [M+H]⁺. Anal. C₂₆H₂₇N₅O (C, H, N).

6.1.12. General procedure for 16a, 16d and 16g. Compounds **16a**, **16d** and **16g** were obtained starting from **15a-c** following the same procedure described for **5a**, **5d** and **5g**.

6.1.12.1. 3-Benzyl-1-cyclohexyl-9-phenylpyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-one [16a]. Yield = 98%; mp = 209-213 °C (EtOH); ¹H-NMR (CDCl₃) δ 1.30-1.75 (m, 5H, cC₆H₁₁), 1.85-1.95 (m, 1H, cC₆H₁₁), 2.00-2.15 (m, 4H, cC₆H₁₁), 3.15-3.25 (m, 1H, cC₆H₁₁), 5.50 (s, 2H, CH₂Ph), 7.25-7.40 (m, 4H, Ar), 7.50-7.60 (m, 5H, Ar), 8.05 (d, 2H, Ar), 9.45 (s, 1H, Ar). ¹³C-NMR (CDCl₃) δ 157.63, 157.22, 146.74, 142.88, 136.34, 136.04, 131.00, 130.10, 129.22, 129.13, 128.49, 127.90, 126.85, 118.53, 99.86, 55.42, 42.12, 31.26, 26.63,

25.96. ESI-MS calcd. for C₂₇H₂₅N₅O, 435.52; found: *m/z* 436.20 [M+H]⁺. Anal. C₂₇H₂₅N₅O (C, H, N).

6.1.13. General procedure for 16b,c 16f and 16h,i. Compounds **16b,c**, **16f** and **16h,i** were obtained starting from **15a-c** following the general procedure described for **5b,c**, **5e,f** and **5h,i**. For compounds **16h** and **16i** a catalytic amount of concentrated sulfuric acid was added to the reaction mixture and the reaction was carried out at room temperature for 2h. After cooling the crude precipitate was recovered by suction. Compound **16c** was extracted with CH₂Cl₂ (3 x 15 mL) from reaction mixture.

6.1.14. General procedure for 17a-i. A mixture of appropriate pyrazolopyrimidopyridazinone **16a-i** (0.3 mmol) and Lawesson's reagent (0.6 mmol) in toluene (6.5 mmol) was heated at 140 °C for 1-5 h. After cooling the solid was recovered by suction and recrystallized from EtOH.

6.1.14.1. 3-Benzyl-1-cyclohexyl-9-phenylpyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-thione [17a]. Yield = 23%; mp = 258-262 °C dec. (EtOH); ¹H-NMR (CDCl₃) δ 1.40-1.80 (m, 4H, cC₆H₁₁), 1.90-2.20 (m, 6H, cC₆H₁₁), 3.20-3.40 (m, 1H, cC₆H₁₁), 6.10 (s, 2H, CH₂Ph), 7.25-7.40 (m, 3H, Ar), 7.50-7.65 (m, 6H, Ar), 8.05 (d, 2H, Ar), 9.50 (s, 1H, Ar). ¹³C-NMR (CDCl₃) δ 173.54, 157.19, 145.94, 142.41, 136.95, 135.84, 130.80, 130.7, 129.02, 128.98, 128.17, 127.57, 127.02, 119.02, 100.15, 55.33, 41.72, 31.24, 26.58, 25.92. ESI-MS calcd. for C₂₇H₂₅N₅S, 451.59; found: *m/z* 4452.38 [M+H]⁺. Anal. C₂₇H₂₅N₅S (C, H, N).

6.2. Biological Assays

6.2.1 Adenosine Receptor Binding Assay.

Radioligand binding competition assays were performed using A₁, A_{2A}, and A₃ human receptors expressed in transfected CHO cells, kindly supplied by Prof. K.N. Klotz, Wurzburg University, Germany [42,43]. [³H]DPCPX, [³H]NECA, and [¹²⁵I]AB-MECA were obtained from DuPont-NEN (Boston, MA). ADA was from Sigma Chemical Co. (St. Louis, MO). All other reagents were from standard commercial sources and of the highest commercially available grade.

6.2.1.1 Human A₁ Adenosine Receptors.

Aliquots of cell membranes (30 μg proteins) were incubated at 25 °C for 180 min in 500 μL of T1 buffer (50 mM Tris-HCl, 2 mM MgCl₂, 2 units/mL ADA, pH 7.4) containing [³H]DPCPX (3 nM, DuPont-NEN, Boston, MA) and six different concentrations of the newly synthesized compounds. Non-specific binding was determined in the presence of 50 μM R-PIA [44]. The dissociation constant (K_d) of [³H]DPCPX in hA₁ CHO cell membranes was 3 nM.

6.2.1.2. Human A_{2A} Adenosine Receptors.

Aliquots of cell membranes (30 μg) were incubated at 25 °C for 90 min in 500 μL of T2 buffer (50 mM Tris-HCl, 2 mM MgCl₂, 2 units/mL ADA, pH 7.4) in the presence of 30 nM of [³H]NECA and six different concentrations of the newly synthesized compounds. Non-specific binding was determined in the presence of 100 μM R-PIA [44]. The dissociation constant (K_d) of [³H]NECA in hA_{2A} CHO cell membranes was 30 nM.

6.2.1.3. Human A₃ Adenosine Receptors.

Aliquots of cell membranes (30 μ g) were incubated at 25 °C for 90 min in 100 μ L of T3 buffer (50 mM Tris-HCl, 10 mM MgCl₂, 1 mM EDTA, 2 units/mL ADA, pH 7.4) in the presence of 1.4 nM [¹²⁵I]AB-MECA and six different concentrations of the newly synthesized compounds. Non-specific binding was determined in the presence of 50 μ M R-PIA [44]. The dissociation constant (K_d) of [¹²⁵I]AB-MECA in hA₃ CHO cell membranes was 1.4 nM.

All compounds were routinely dissolved in DMSO and diluted with assay buffer to the final concentration, where the amount of DMSO never exceeded 2%. Percentage inhibition values of specific radiolabelled ligand binding at 1-10 μ M concentration are means \pm SEM of at least three determinations.

6.2.2. A₁ and A_{2B} adenosine receptor functional assay.

Intracellular cyclic AMP (cAMP) levels were measured using a competitive protein binding method [44]. CHO cells, expressing recombinant human ARs, were harvested by trypsinization. After centrifugation and re-suspension in medium, cells (~ 30000) were plated in 24-well plates in 0.5 mL of medium. After 24 h, the medium was removed, and the cells were incubated at 37 °C for 15 min with 0.5 mL of Dulbecco's Modified Eagle Medium (DMEM) in the presence of adenosine deaminase (ADA) (1U/mL) and the phosphodiesterase inhibitor Ro20-1724 (20 μ M). The pharmacological profile of the compounds towards A_{2B} ARs was evaluated by assessing cAMP accumulation in the absence or presence of the agonist NECA (100 nM). The antagonist profile of the compounds towards A₁ ARs was evaluated by assessing their ability to counteract NECA-mediated inhibition of cAMP accumulation in the presence of 1 μ M forskolin, as non-selective adenylate cyclase (AC) activator. Cells were incubated in the reaction medium (15 min at 37 °C) with different concentrations of target compounds (0.1 nM- 1 μ M) and then were treated with the agonist [43].

Following incubation, the reaction was terminated by the removal of the medium and the addition of 0.4 N HCl. After 30 min, lysates were neutralized with 4 N KOH, and the suspension was centrifuged at 800 g for 5 min. For the determination of cAMP production, bovine adrenal cAMP binding protein was incubated with [³H]cAMP (2 nM) and 50 µl of cell lysate or cAMP standard (0-160 pmol) at 0 °C for 150 min in a total volume of 300 µl. Bound radioactivity was separated by rapid filtration through GF/C glass fiber filters and washed twice with 4 mL 50 mM Tris-HCl, pH 7.4. The radioactivity was measured by liquid scintillation spectrometry.

6.2.3. In vivo studies

Animal handling was carried out according to the European Community guidelines for animal care (DL 116/92, application of the European Communities Council Directive 86/609/EEC). The ethical policy of the University of Florence conforms with the Guide for the Care and Use of Laboratory Animals of the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996; University of Florence assurance number: A5278-01). Formal approval to conduct the experiments described herein was obtained from the animal subjects review board of the University of Florence. For the experiment described male Swiss albino mice (23-25 g) were used. The animals were fed with a standard laboratory diet and tap water ad libitum, and kept at 23 ± 1 °C with a 12 h light/dark cycle, light on at 7 a.m.

6.2.3.1. Drugs

CPA and DCPCX were dissolved in isotonic (NaCl 0.9%) saline solution while AT-11 in carboxymethylcellulose (CMC) and administered by gavage.

6.2.3.2. Passive-avoidance test

The test was performed according to the step-through method described by Jarvik and Kopp [46] with modifications. The apparatus consisted of a two-compartment acrylic box with a lighted compartment connected to a darkened one by a guillotine door. In the original method mice received a punishing electrical shock as soon as they entered the dark compartment, while in our modified method, mice, after their entry into the dark compartment, received a punishment consisting of a fall into a cold water bath (10°C). For this purpose the dark chamber was constructed with a pitfall door. The latency times for entering the dark compartment were measured in the training test and after 24 h in the retention test. The maximum entry latency allowed in the retention session was 120 s.

6.2.3.3. Rota-rod test

The apparatus consisted of a base platform and a rotating rod of 3 cm diameter with a non-slippery surface. The rod was placed at a height of 15 cm from the base. The rod, 30 cm in length, was divided into 5 equal sections by 6 disks. Thus, up to 5 mice were tested simultaneously on the apparatus, with a rod-rotating speed of 16 r.p.m. The integrity of motor coordination was assessed on the basis of the number of falls from the rod in 30 s according to Vaught et al. [47]. Those mice scoring less than 3 and more than 6 falls in the pretest were rejected (20%).

6.2.4. Data analysis

All binding and functional data were analyzed using the non-linear regression curve fitting program GraphPad, version 5.0. IC₅₀ and Ki values were directly obtained from the dose

response curves. All values obtained by in vitro assays are the mean \pm S.E.M of at least three different experiments, each performed in duplicate.

Results obtained by in vivo studies were expressed as the means \pm S.E.M. and an analysis of variance was performed by ANOVA. A Fisher's protected least significant difference procedure was used as post-hoc comparison. Each value represents the mean of 12 mice. P values of less than 0.05 or 0.01 were considered significant. Data were analyzed using the "Origin 7.5" software.

References

- [1] Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol. Rev.* **2001**, *53*, 527-552.
- [2] Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Linden, J.; Muller, C. E. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. *Pharmacol. Rev.* **2011**, *63*, 1-34.
- [3] Jacobson, K. A.; Knutsen, L. J. S. P₁ and P₂ purine and pyrimidine receptor ligands. In purinergic and pyrimidinergetic signalling. Abbracchio, M. P., Williams, M., Eds.; *Handbook of Experimental Pharmacology*, Vol 151/1; Springer: Berlin. 2001, 129-175.
- [4] Fredholm, B. B.; Arslan, G.; Haldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes. *Naunyn-Schmied. Arch. Pharmacol.* **2000**, *362*, 364-374.

- [5] Poulsen, S. A.; Quinn, R. J. Adenosine receptors: new opportunities for futures drugs. *Bioorg. Med. Chem.* **1998**, *6*, 619-641.
- [6] Abbracchio, M. P.; Brambilla, R.; Ceruti, S.; Kim, H. O.; von Lubitz, D. K.; Jacobson, K. A.; Cattabeni, F. G-protein-dependent activation of phospholipase-C by adenosine A₃ receptor in rat brain. *Mol. Pharmacol.* **1995**, *48*, 1038-1045.
- [7] Ali, H.; Choi, O. H.; Fraundorfer, P. F.; Yamada, K.; Gonzaga, H. M. S.; Beaven, M. A. Sustained activation of phospholipase-D via adenosine A₃ receptors is associated with enhancement of antigen-ionophore-induced and Ca²⁺-ionophore-induced secretion in a rat mast-cell line. *J. Pharmacol. Exp. Ther.* **1996**, *276*, 837-845.
- [8] Shneyvays, V.; Leshem, D.; Zinman, T.; Mamedova, L. K.; Jacobson, K. A.; Shainberg, A. Role of adenosine A₁ and A₃ receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. *Am. J. Physiol. Heart Circ. Physiol.* **2005**, *288*, H2792-H2801.
- [9] Jacobson, K. A. Introduction to adenosine receptors as therapeutic targets. *Handb. Exp. Pharmacol.* **2009**, *193*, 1-24.
- [10] Muller, C. E.; Ferrè, S. Blocking striatal adenosine A_{2A} receptors: a new strategy for basal ganglia disorders. *Recent Pat. CNS Drug Discovery* **2007**, *2*, 1-21.
- [11] Paoletta, S.; Federico, S.; Spalluto, G.; Moro, S. Receptor-driven identification of novel human adenosine antagonists as potential therapeutic agents. *Method Enzymol.* **2010**, *485*, 225-244.
- [12] Ribeiro, J. A.; Sebastiao, A. M.; de Mendica, A. Adenosine receptors in the nervous system: patophysiological implications. *Progr. Neurobiol.* **2003**, *68*, 377-392.

- [13] Lopes, L. V.; Sebastiao, A. M.; Ribeiro, J. A. Adenosine and Related Drugs in Brain Diseases: Present and Future in Clinical Trials. *Curr. Top. Med. Chem.* **2011**, *11*, 446-456.
- [14] Suzuki, F.; Shimada, J.; Shiozaki, S.; Ichikawa, S.; Ishii, A.; Nakamura, J.; Nonaka, H.; Kobayashi, H.; Fuse, E. Adenosine A₁ antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance. *J. Med. Chem.* **1993**, *36*, 2508-2518.
- [15] Tabata, K.; Matsumoto, K.; Murakami, Y.; Watanabe, H. Ameliorative effects of paeoniflorin, a major constituent of peony root, on adenosine A₁ receptor-mediated impairment of passive avoidance performance and long-term potentiation in the hippocampus. *Biol. Pharm. Bull.* **2001**, *24*, 496-500.
- [16] Pereira, G. S.; Mello e Souza, T.; Vinadé, E. R.; Choi, H.; Rodrigues, C.; Battastini, A. M.; Izquierdo, I.; Sarkis, J. J.; Bonan, C. D. Blockade of adenosine A₁ receptors in the posterior cingulate cortex facilitates memory in rats. *Eur. J. Pharmacol.* **2002**, *437*, 151–154.
- [17] Mioranza, S.; Costa M. S.; Botton, P. H. S.; Ardais, A. P.; Matte, V. L.; Espinosa, J.; Souza, D. O.; Porciúncula, L. O. Blockade of adenosine A₁ receptors prevents methylphenidate-induced impairment of object recognition task in adult mice. *Prog. Neuro-Psychoph.* **2011**, *3*, 169–176.
- [18] Florian, C.; Vecsey, C. G.; Halassa, M. M.; Haydon, P. G.; Abel, T. Astrocyte-derived adenosine and A₁ receptor activity contribute to sleep loss-induced deficits in hippocampal synaptic plasticity and memory in mice. *J. Neurosci.* **2011**, *31*, 6956 – 6962.

- [19]Pereira G. S.; Rossato J. I.; Sarkis J. J.; Cammarota M.; Bonan C. D., Izquierdo, I. Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat. *Neurobiol. Learn. Mem.* **2005**, *83*, 217–223
- [20]Prediger, R. D.; Takahashi, R. N. Modulation of short-term social memory in rats by adenosine A₁ and A_{2A} receptors. *Neurosci. Lett.* **2005**, *376*, 160–165.
- [21]Brown, R. A.; Spina, D.; Page, C. P. Adenosine receptors and asthma. *J. Pharmacol.* **2008**, *153*, 878-901.
- [22]Schenone, S.; Bruno, C.; Musumeci, F.; Bruno, O.; Botta, M. A₁ receptors ligands: past, present and future trends. *Curr. Top. Med. Chem.* **2010**, *10*, 329-336.
- [23]Ensor, C. R.; Russell, S. D. Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. *Exp. Opin. Pharmacother.* **2010**, *11*, 2405-2415.
- [24]Mitrovic, V.; Seferovic, P.; Dodic, S.; Krotin, M.; Neskovic, A.; Dickstein, K.; de Voogd H.; Bocker, C.; Ziegler, D.; Godes, M.; Nakov, R.; Essers, H.; Verboom, C.; Hocher, B. Cardio-renal effects of the A₁ adenosine receptor antagonist SLV320 in patients with heart failure. *Circ. Heart Fail.* **2009**, *2*, 523-531.
- [25] Slawsky, M. T.; Givertz, M. M. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. *Expert Opin. Pharmacother.* **2009**, *10*, 311-322.
- [26]Voors, A. A.; Dittrich, H. C.; Massie, B. M.; DeLucca, P.; Mansoor, G. A.; Metra, M.; Cotter, G.; Weatherley, B. D.; Ponikowski, P.; Teerlink, J. R.; Cleland, J. G.; O'Connor C. M.; Givertz, M. M. Effects of the adenosine A₁ receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-controlled randomized study of the selective adenosine A₁ receptor antagonist Rolofylline for patients hospitalized with Acute


- decompensated heart failure and volume overload to assess treatment effect on congestion and renal function). *J. Am. Coll. Cardiol.* **2011**, *57*, 1899-1907.
- [27] Jacobson, K. A.; van Galen, P. J. M.; Williams, M. Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. *J. Med. Chem.* **1992**, *35*, 407-422.
- [28] Giovannoni, M. P.; Vergelli, C.; Cilibrizzi, A.; Crocetti, L.; Biancalani, C.; Graziano, A.; Dal Piaz, V.; Loza, M. I.; Cadavid, M. I.; Diaz, J. L. Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A₁ adenosine receptor ligands. *Bioorg. Med. Chem.* **2010**, *18*, 7890-7899.
- [29] Graziano, A.; Giovannoni, M. P.; Cilibrizzi, A.; Crocetti, L.; Dal Piaz, V.; Vergelli, C.; Trincavelli, M. L.; Martini, C.; Giacomelli, C. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones fluoroderivatives as human A₁ adenosine receptor ligands. *Acta Chim. Slov.* **2012**, *59*, 648-655.
- [30] Dal Piaz, V.; Ciciani, G.; Chimichi, S. Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-7(8H)-one: a new heterocyclic ring system from isoxazolopyridazinones. *Heterocycles* **1986**, *24*, 3143-3148.
- [31] Feixas, J.; Giovannoni, M. P.; Vergelli, C.; Gavaldà, A.; Cesari, N.; Graziano, A.; Dal Piaz, V. New Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 2381-2384.
- [32] Giovannoni, M.P.; Vergelli, C.; Biancalani, C.; Cesari, N.; Graziano, A.; Biagini, P.; Gracia, J.; Gavaldà, A.; Dal Piaz, V. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction. *J. Med. Chem.* **2006**, *49*, 5363-5371.

- [33] Costantino, L.; Rastelli, G.; Gamberini, M.C.; Giovannoni, M.P.; Dal Piaz, V.; Vianello, P.; Barlocco, D. Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors. *J. Med. Chem.* **1999**, *42*, 1894-1900.
- [34] Dal Piaz, V.; Aguilar Izquierdo, N.; Buil Albero, M.A.; Carrascal Riera, M.; Gracia Ferrer, J.; Giovannoni, M.P.; Vergelli, C. New pyridazin-3(2H)-one derivatives. PTC Int. Appl. WO 2004058729, 2004, 212 pp.
- [35] Dal Piaz, V.; Castellana, M.C.; Vergelli, C.; Giovannoni, M.P.; Gavaldà, A.; Segarra, V.; Belata, J.; Ryder, H.; Palacios, J.M. Synthesis and evaluation of some pyrazolo[3,4-d]pyridazinones and analogues as PDE5 inhibitors potentially useful as peripheral vasodilator agents. *J. of Enz. Inhib. and Med. Chem.* **2002**, *17*, 227-233.
- [36] Giovannoni, M.P.; Cesari, N.; Vergelli, C.; Graziano, A.; Biancalani, C.; Biagini, P.; Ghelardini, C.; Vivoli, E.; Dal Piaz, V. 4-Amino-5-substituted-3(2H)-pyridazinones as orally active antinociceptive agents: synthesis and studies on the mechanism of action. *J. Med. Chem.* **2007**, *50*, 3945-3953.
- [37] Gelin, S.; Rouet, J. Reaction of nucleophiles with β -diketones. *Bull. Soc. Chim. Fr.* **1971**, *6*, 2179-2184.
- [38] Fargeas, V.; Baalouch, M.; Metay, E.; Baffreau, J.; Menard, D.; Gosselin, P.; Berge, J.P.; Barthomeuf, C.; Lebreton, J. New access to 1,3-diketones from aldehydes. *Tetrahedron*, **2004**, *60*, 10359-10364.
- [39] Protzmann, G.; Wiese, K-D.; Brueschken, W. Condensation of aldehydes with ketones to α,β -unsaturated ketones by multiphase reaction in a packed tube reactor. Eur. Pat. Appl. EP1231199, 2002.

- [40] Dal Piaz, V.; Pinzauti, S.; Lacrimini, P. Condensation of some 3-methylisoxazolo[3,4-d]pyridazin-7(6H)ones with aromatic aldehydes. *J. Heterocycl. Chem.* **1976**, *13*, 409-410.
- [41] Güngör T.; Chen Y.; Golla R.; Ma Z.; Corte J.R.; Northrop J.P.; Bin B.; Dickson J.K.; Stouch T.; Zhou R.. Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. *J. Med. Chem.* **2006**, *49*, 2440–2455.
- [42] Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohse, M. J. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. *N-S Arch. Pharmacol.* **1998**, *357*, 1–9.
- [43] Taliani, S.; Trincavelli, M. L.; Cosimelli, B.; Laneri, S.; Severi, E.; Barresi, E.; Pugliesi, I.; Daniele, S.; Giacomelli, C.; Greco, G.; Novellino, E.; Martini, C.; Da Settimo, F. Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindeole derivatives. *Eur. J. Med. Chem.* **2013**, *69*, 331-337.
- [44] Da Settimo, F.; Primofiore, G.; Taliani, S.; La Motta, C.; Novellino, E.; Greco, G.; Lavecchia, A.; Cosimelli, B.; Iadanza, M.; Klotz, K.-N.; Tuscano, D.; Trincavelli, M. L.; Martini, C. A₁ adenosine receptor antagonists, 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4-(10H)-ones (ATBIs) and N-alkyl and N-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs): different recognition of bovine and human binding sites. *Drug Dev. Res.* **2004**, *63*, 1-7.
- [45] Nordstedt, C.; Fredholm, B. B. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. *Anal. Biochem.* **1990**, *189*, 231–234.

[46] Jarvik, M. E.; Kopp, R. An improved one-trial passive avoidance learning situation.
Psychol. Rep. **1967**, *21*, 221-224.

[47]Vaught, J.; Pelley, K.; Costa, L. G.; Sether, P.; Enna, S. J. A comparison of the
antinociceptive responses to GABA- receptor agonists THIP and baclofen.
Neuropharmacology **1985**, *24*, 211-216.

Table 1. Binding activity at human A₁, A_{2A} and A₃ ARs of compounds **5a-i****5a-i**

Comp.	Ar	R ₆	hA ₁ ^{a,b} Ki (nM) or % inhib at 10 μM	hA _{2A} ^{a,c} Ki (nM) or % inhib at 10 μM	hA ₃ ^{a,d} Ki (nM) or % inhib at 10 μM
5a	4-Cl-Ph	H	26%	56%	31%
5b	4-Cl-Ph	CH ₃	24%	28%	25%
5c	4-Cl-Ph	CH ₂ CH ₃	35%	10%	51%
5d	2-Thienyl	H	45%	51.0±3.1	16%
5e	2-Thienyl	CH ₃	21%	2595.4±160.2	15%
5f	2-Thienyl	CH ₂ CH ₃	16%	65%	30%
5g	3-Thienyl	H	26%	69.2±4.4	24%
5h	3-Thienyl	CH ₃	8%	57%	37%
5i	3-Thienyl	CH ₂ CH ₃	5%	41%	36%
A	3-Pyridyl	H	11.4±2.2	805.1±374.5	21%
DPCPX			3.2±0.2 ^b	260.3±18.2 ^b	-


^a Values are means ± S.E.M of three separate experiments, each performed in duplicate.

^b Displacement of [³H]DPCPX binding in A₁ CHO cells membranes.

^c Displacement of [³H]NECA binding in A_{2A} CHO cells membranes.

^d Displacement of [¹²⁵I]AB-MECA binding in A₃ CHO cells membranes.

Table 2. Binding activity at human A₁, A_{2A} and A₃ adenosine receptors of compounds **16a-i** and **17a-i**



16a-i, 17a-i

Comp.	R ₁	R ₆	X	hA ₁ ^{a,b} Ki (nM) or % inhib at 10 μM	hA _{2A} ^{a,c} Ki (nM) or % inhib at 10 μM	hA ₃ ^{a,d} Ki (nM) or % inhib at 10 μM
16a	cC ₆ H ₁₁	H	O	172.5±15.2	56%	308.4±30.2
16b	cC ₆ H ₁₁	CH ₃	O	9.5±0.7	7%	35%
16c	cC ₆ H ₁₁	CH ₂ CH ₃	O	15.2±1.1	0%	40%
16d	cC ₅ H ₉	H	O	32.3±3.1	75.5±7.9	64.0±2.7
16e ^[25]	cC ₅ H ₉	CH ₃	O	6.2±0.2	53%	41%
16f	cC ₅ H ₉	CH ₂ CH ₃	O	3.5±0.4	662.4±60.8	43%
16g	nC ₄ H ₉	H	O	1.9±0.2	44%	193.2±1.4
16h	nC ₄ H ₉	CH ₃	O	3.4±0.3	46%	5%
16i	nC ₄ H ₉	CH ₂ CH ₃	O	1.4±0.1	7%	20%
17a	cC ₆ H ₁₁	H	S	9.5±0.9	8%	31%
17b	cC ₆ H ₁₁	CH ₃	S	33%	0%	30%
17c	cC ₆ H ₁₁	CH ₂ CH ₃	S	31%	0%	42%
17d	cC ₅ H ₉	H	S	12.9±1.2	37%	54%
17e	cC ₅ H ₉	CH ₃	S	51%	18%	13%
17f	cC ₅ H ₉	CH ₂ CH ₃	S	4.7±0.5	35%	24%
17g	nC ₄ H ₉	H	S	2.4±0.2	34%	43%
17h	nC ₄ H ₉	CH ₃	S	50%	0%	16%
17i	nC ₄ H ₉	CH ₂ CH ₃	S	61%	3%	37%
A	3-Pyridyl	H	O	11.4±2.2	805.1±374.5	21%
DPCPX				3.2±0.2 ^b	260.3±18.2 ^b	-

^a Values are means ± S.E.M. of three separate experiments, each performed in duplicate.

^b Displacement of [³H]DPCPX binding in A₁ CHO cells membranes.

^c Displacement of [³H]NECA binding in A_{2A} CHO cells membranes.

^d Displacement of [¹²⁵I]AB-MECA binding in A₃ CHO cells membranes.

Table 3. Effects of compounds **16b-i** and **17a-g** on cAMP Production in CHO Cells Expressing Human A_{2B} AR.^a

Compound	% cAMP production (vs agonist maximal effect set to 50%) ^b	
	A _{2B} AR	
	- agonist	+ agonist
16b	2.1 ± 0.2	57.8 ± 1.9
16i	4.6 ± 0.8	61.0 ± 3.8
17a	4.8 ± 0.3	58.9 ± 3.9
17g	3.5 ± 0.8	61.9 ± 1.6

^a The effect of each compound (10 µM) was evaluated on cAMP production in CHO cells expressing human A_{2B} ARs (see biological section). Each compound was tested alone or in the presence of an EC₅₀ concentration of agonist NECA (determined on the same day as each assay). ^b Data are expressed as percentage of cAMP production versus agonist maximal effect (50%). All data represent the mean ± SEM of at two different experiments each performed in duplicate.

Table 4. Effect of **16i** in comparison with DPCPX on amnesia induced by N6-cyclopentyladenosine (CPA) in the mouse passive avoidance test

Treatment ^a	Training session ^b	Retention session ^b
CMC+SALINE	15.9 ± 3.5	97.2 ± 9.5
CMC + CPA	16.6 ± 4.1	61.2 ± 9.0*
16i 3 mg/kg + CPA	16.8 ± 4.3	56.7 ± 9.5*
16i 10 mg/kg + CPA	13.7 ± 3.9	96.1 ± 8.2§
16i 30 mg/kg + CPA	19.4 ± 3.8	88.2 ± 9.4§
DPCPX mg/kg + CPA	16.5 ± 4.2	91.9 ± 11.3§

^a **16i** (3-30 mg/kg i.p.) and DPCPX (3 mg/kg i.p.) were administered 30 min before training session while CPA (1.6 mg/kg i.p.) was given immediately after punishment.

^b Each value represents the mean of 10 - 12 mice. * P < 0.01 versus CMC-Saline treated group; §P < 0.01 versus CMC+CPA treated group.

Captions

Scheme 1. Synthesis of pyrazolo[1',5':1:6]pyrimido[4,5-d]pyridazin-4(3H)-ones **5a-i**

Reagents and conditions: (a) PhCH₂Cl, anhydrous DMF, anhydrous K₂CO₃, 80 °C, 2-3 h; (b) PhCHO, MeONa, anhydrous MeOH, reflux, 1-30 min; (c) NH₂NH₂, EtOH, rt, 2-4h; (d) for R = H: CH(OC₂H₅)₃, H₂SO₄ conc., anhydrous DMF, reflux, 30 min-2 h; for R = CH₃ or C₂H₅ appropriate anhydride, reflux, 30 min-2 h.

Scheme 2. Synthesis of pyrazolo[1',5':1:6]pyrimido[4,5-d]pyridazin-4(3H)-ones **16a-i** and pyrazolo[1',5':1:6]pyrimido[4,5-d]pyridazin-4(3H)-thiones **17a-i**


Reagents and conditions: (a) EtONa, anhydrous EtOH, 0 °C; (b) NH₂NH₂, EtOH, rt, 1-2 h; (c) PhCH₂Br, anhydrous DMF, anhydrous K₂CO₃, 80 °C, 2-3 h; (d) PhCHO, MeONa, anhydrous MeOH, reflux, 1-30 min; (e) NH₂NH₂, MeOH, rt, 2-4h; (f) for R = H: CH(OC₂H₅)₃, H₂SO₄ conc., anhydrous DMF, reflux, 30min-2h; for R = CH₃ or C₂H₅ appropriate anhydride, reflux, 30 min-2h; (g) Lawesson's reagent, toluene, 140 °C, 1-5h.

Figure Legend



Figure 1. Selective A₁R antagonists and reference compound A

Figure 2. Effects of **16e**, **16i**, **5c** and **5f** on NECA-mediated inhibition of cAMP accumulation in human A₁ AR-transfected CHO cells. CHO cells were treated with 1 μM forskolin and 100 nM NECA in the absence or presence of different concentrations of the compounds (1 nM-10 μM). After 15 min incubation, the reaction was stopped and the intracellular cAMP levels were quantified. The data are expressed as the percentage of the cAMP intracellular levels with respect to forskolin, which was set to 100%, and represent the mean ± SEM of at least three different experiments. Each experiment was performed in duplicate.


Scheme 1



Scheme 2




6, 8-15 R	
a	cC ₆ H ₁₁
b	cC ₅ H ₉
c	nC ₄ H ₉




16-17	R ₁	R ₆
a	cC ₆ H ₁₁	H
b	cC ₆ H ₁₁	CH ₃
c	cC ₆ H ₁₁	CH ₂ CH ₃
d	cC ₅ H ₉	H
e	cC ₅ H ₉	CH ₃
f	cC ₅ H ₉	CH ₂ CH ₃
g	nC ₄ H ₉	H
h	nC ₄ H ₉	CH ₃
i	nC ₄ H ₉	CH ₂ CH ₃


Figure 1




BG9928



SLV320



KW3902



A

$hA_1 = 11.4 \text{ nM}$
$hA_{2A} = 805.1 \text{ nM}$
$hA_3 = 21\% (10 \text{ mM})$

Figure 2

